Neuroscience of Orofacial Pain & Temporomandibular Disorders Program | National Institute of Dental and Craniofacial Research

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock () or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Neuroscience of Orofacial Pain & Temporomandibular Disorders Program

Notice of Intent to Publish a Funding Opportunity Announcement for In Vivo Non-Invasive Optical Approaches for Biological systems (UG3/HU3 Clinical Trial Not Allowed)

NOT-RM-24-014

Innovation Corps (I-Corps TM) at NIH Program for NIH and CDC Translational Research (Admin Supp Clinical Trial NOT Allowed)

PA-25-212

Notice of Special Interest (NOSI): Administrative Supplement for Research and Capacity Building Efforts Related to Bioethical Issues (Admin Supp Clinical Trial Optional)

NOT-OD-25-015

Notice of pre-Application Technical Assistance Webinar for RFA-DE-25-003 TMD Collaborative for IMproving PAtient-Centered Translational Research (TMD IMPACT) (U54 Clinical Trial Optional)

NOT-DE-25-037

TMD Collaborative for IMproving PAtient-Centered Translational Research (TMD IMPACT) (U54 Clinical Trial Optional)

RFA-DE-25-003

Human Brain Single-cell Genomics Explorer (U24 - Clinical Trial Not Allowed)

RFA-NS-24-038

Notice of Special Interest (NOSI): Research on the Health of Women of Underrepresented, Underserved, and Underreported (U3) Populations (Admin Supp Clinical Trial Optional)

NOT-OD-24-179

NIDCR Notice of Participation in PA-25-080 "NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed)"

NOT-DE-25-041

Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)

PAR-24-294

Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)

PAR-24-293